Stocks
Cardiff Oncology, Inc.CRDF
NASDAQHealthcareBiotechnology$0.93
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing oncology therapies, with its lead candidate, onvansertib, being evaluated in trials for colorectal and other cancers. Investors track the company for its focus on targeting PLK1, a protein involved in cell division, and its potential to improve outcomes in difficult-to-treat solid tumors.
52W Range: $0.76-$3.31
Congressional Interest in Cardiff Oncology, Inc. (CRDF)
No congressional trades have been disclosed for Cardiff Oncology, Inc. (CRDF) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading CRDF?
No congressional trades found for this stock.